As TP53 was frequently mutated in patients with KMT2C mutations in the OrigiMed (75%) and Rizvi (72%) cohorts, we further confirmed the synergetic effect of epigenetic‐related genes and tumor suppressor gene mutations as predictive biomarkers for cancer immunotherapies. Here, TP53 is linked to cancer.